Nuclea Biotechnologies Inc., a Pittsfield company focused on biomarkers, announced a new partnership with Boston Medical Center that has the potential to lead to more effective treatments for people with breast and prostate cancers.
Biomarkers are a component in the field of personalized medicine and they can predict which treatments will be effective for certain patients.
Under the partnership, Nuclea will pay Boston Medical Center about $1.4 million over the next three years to support the research. In return, Nuclea will have right of first refusal of commercialization on all new discoveries relating to biomarker development, biomarker arrays, and methods involving new diagnostic and novel radiological interpretations, Nuclea said in a press release.
Boston Globe Staff